Premium
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program
Author(s) -
Smith Malcolm A.,
Maris John M.,
Lock Richard,
Kolb E. Anders,
Gorlick Richard,
Keir Stephen T.,
Carol Hernan,
Morton Christopher L.,
Reynolds C. Patrick,
Kang Min H.,
Houghton Peter J.
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22797
Subject(s) - neuroblastoma , in vivo , polyamine , medicine , ependymoma , sarcoma , rhabdomyosarcoma , in vitro , spermine , population , pediatric cancer , cancer research , cell culture , cancer , pharmacology , pathology , oncology , biology , biochemistry , genetics , microbiology and biotechnology , environmental health , enzyme
Background PG11047 is a novel conformationally restricted analog of the natural polyamine, spermine that lowers cellular endogenous polyamine levels and competitively inhibits natural polyamine functions leading to cancer cell growth inhibition. The activity of PG11047 was evaluated against the PPTP's in vitro and in vivo panels. Procedures PG11047 was evaluated against the PPTP in vitro panel using 96 hr exposure at concentrations ranging from 10 nM to 100 µM. It was tested against the PPTP in vivo panels at a dose of 100 mg/kg administered by the intraperitoneal route weekly for 6 weeks. Results In vitro PG11047 demonstrated a concentration–response pattern consistent with cytostatic activity. The median EC 50 for PG11047 was 71 nM. Cell lines of the Ewing sarcoma panel had a lower median EC 50 value compared to the remaining cell lines in the panel, while cell lines of the neuroblastoma panel had a higher median EC 50 value. In vivo PG11047 induced significant differences in EFS distribution compared to control in 5 of 32 (15.6%) of the evaluable solid tumor xenografts and in 0 of 7 (0%) of the evaluable ALL xenografts. The single case of tumor regression occurred in an ependymoma xenograft. Conclusions Further pediatric development of PG11047 will require better defining a target population and identifying combinations for which there is a tumor‐selective cytotoxic effect. The regression observed for an ependymoma xenograft and the exquisite sensitivity of some Ewing sarcoma cell lines to the antiproliferative effects of PG11047 provide leads for further preclinical investigations. Pediatr Blood Cancer 2011; 57: 268–274. © 2011 Wiley‐Liss, Inc.